...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Developing whole mycobacteria cell vaccines for tuberculosis: Workshop proceedings, Max Planck Institute for Infection Biology, Berlin, Germany, July 9, 2014
【24h】

Developing whole mycobacteria cell vaccines for tuberculosis: Workshop proceedings, Max Planck Institute for Infection Biology, Berlin, Germany, July 9, 2014

机译：开发用于结核的全分枝杆菌细胞疫苗：研讨会程序，马克斯·普朗克感染生物学研究所，德国柏林，2014年7月9日

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

On July 9, 2014, Aeras and the Max Planck Institute for Infection Biology convened a workshop entitled "Whole Mycobacteria Cell Vaccines for Tuberculosis" at the Max Planck Institute for Infection Biology on the grounds of the Charite Hospital in Berlin, Germany, close to the laboratory where, in 1882, Robert Koch first identified Mycobacterium tuberculosis (Mtb) as the pathogen responsible for tuberculosis (TB). The purpose of the meeting was to discuss progress in the development of TB vaccines based on whole mycobacteria cells. Live whole cell TB vaccines discussed at this meeting were derived from Mtb itself, from Bacille Calmette-Guerin (BCG), the only licensed vaccine against TB, which was genetically modified to reduce pathogenicity and increase immunogenicity, or from commensal non-tuberculous mycobacteria. Inactivated whole cell TB and non-tuberculous mycobacterial vaccines, intended as immunotherapy or as safer immunization alternatives for HIV+ individuals, also were discussed. Workshop participants agreed that TB vaccine development is significantly hampered by imperfect animal models, unknown immune correlates of protection and the absence of a human challenge model. Although a more effective TB vaccine is needed to replace or enhance the limited effectiveness of BCG in all age groups, members of the workshop concurred that an effective vaccine would have the greatest impact on TB control when administered to adolescents and adults, and that use of whole mycobacteria cells as TB vaccine candidates merits greater support, particularly given the limited understanding of the specific Mtb antigens necessary to generate an immune response capable of preventing Mtb infection and/or disease.
机译：2014年7月9日，Aeras与马克斯·普朗克感染生物学研究所在德国柏林的Charite医院附近，在马克斯·普朗克感染生物学研究所召开了一个名为“结核分枝杆菌全细胞疫苗”的研讨会。 1882年，罗伯特·科赫（Robert Koch）在实验室首次将结核分枝杆菌（Mtb）鉴定为造成结核病（TB）的病原体。会议的目的是讨论基于完整分枝杆菌细胞的结核病疫苗开发的进展。在本次会议上讨论的活全细胞结核病疫苗来源于Mtb本身，源自Bacille Calmette-Guerin（BCG）的唯一经许可的针对结核病的疫苗，该疫苗经过了基因改造以降低致病性和提高免疫原性，或来源于普通的非结核分枝杆菌。还讨论了灭活的全细胞结核病和非结核分枝杆菌疫苗，它们旨在作为免疫疗法或作为HIV +个体的更安全的免疫替代品。研讨会的参与者一致认为，不完善的动物模型，未知的免疫保护相关因素以及缺乏人类攻击模型都极大地阻碍了结核病疫苗的开发。尽管需要一种更有效的结核病疫苗来替代或增强BCG在所有年龄组中的有限效力，但研讨会成员一致认为，当对青少年和成人给药时，有效的疫苗将对结核病的控制产生最大的影响，并且整个分枝杆菌细胞作为TB疫苗候选者应得到更大的支持，特别是考虑到对特定Mtb抗原的理解有限，这些抗原对于产生能够预防Mtb感染和/或疾病的免疫反应是必需的。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号